Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

ME Therapeutics Provides Scientific Update on In Vivo CAR and Therapeutic mRNA Programs

ME Therapeutics Advances mRNA Pipeline Amidst Price Consolidation at $2.50 Support Level

By The Northwire Desk — AI Analysis Apr 29, 2026 · 09:00 METX · 2.5 ME Therapeutics Holdings Inc.
Executive Summary
  • The most recent release (April 29, 2026) provides a scientific update on In Vivo CAR and therapeutic mRNA programs.
  • Key progress includes dose-dependent single agent efficacy for a STING pathway-targeting mRNA candidate in a mouse colorectal cancer model.
  • The company is advancing a dual CD19/CD22-targeted CAR candidate, combining licensed nanobody assets with clinically tested constructs.
  • Lipid nanoparticle (LNP) formulations are being optimized for effective delivery to human T cells and macrophages.
  • Historical context from October 2025 confirms the licensing of exclusive commercial rights to a CD22 nanobody asset from the National Research Council of Canada (NRC).
  • September 2026 data indicates US Patent No. 12,421,308 was secured for the G-CSF antibody candidate, though metadata dates suggest potential reporting inconsistencies regarding patent grant timing versus news release date.
Material Impact
  • The April 2026 update represents incremental progress rather than a fundamental shift in risk profile or valuation drivers.
  • Preclinical efficacy data is positive but does not guarantee clinical success; the market typically discounts early-stage animal model results without Phase 1 initiation announcements.
  • Previous milestones (October 2025 license deal) were already priced into the stock, which subsequently declined from $6.80 to current levels despite the asset acquisition.
  • The news confirms execution on the pipeline strategy but lacks catalysts such as partnership deals, financing closures, or regulatory approvals that would constitute material positive impact.
  • Given the stock has been flat at $2.50 for months leading up to this release, the market appears to view preclinical updates as routine maintenance of the R&D roadmap rather than a re-rating event.
METX · Price
Company Overview
  • ME Therapeutics Holdings Inc. focuses on immuno-oncology, specifically in vivo CAR cell therapy and therapeutic mRNA programs.
  • Flagship Project: Dual CD19/CD22-targeted CAR candidate designed for leukemia, lymphoma, and autoimmune diseases.
  • Secondary Pipeline: STING pathway-targeting mRNA candidate for solid tumors (colorectal cancer).
  • Lead Asset: G-CSF antibody candidate (H1B11-12) with secured US patent protection.
  • Development Stage: Preclinical to early clinical transition; Phase 1 trial (NCT06208735) is ongoing for the CD22 binder under investigator-driven protocols.
Read the original news release →

More from ME Therapeutics Holdings Inc.

Jun 03, 2026 · 15:13

ME Therapeutics raises $500K via private placement to fund R&D and pursue U.S. listing as stock trades near 52-week lows.

Financings Jan 30, 2026 · 16:26

ME Therapeutics talks pipeline and in vivo CAR plans

Other Jan 28, 2026 · 14:39

SEDAR Interim Financial Statements

None Oct 16, 2025 · 18:53

ME Therapeutics licenses NRC's CD22 nanobody asset

M&A / Property Oct 16, 2025 · 09:00

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

M&A / Property Sep 26, 2025 · 17:04

ME obtains U.S. patent for G-CSF antibody candidate

M&A / Property